Jump to content

Cardiomyopathy

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Hugh2414 (talk | contribs) at 08:12, 22 December 2005 (Tidy-up - but see Talk:Cardiomyopathy). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Cardiomyopathy is the deterioration of the cardiac muscle of the heart wall.

Cardiomyopathy can lead to heart failure as the pumping efficiency of the heart is diminished. People with cardiomyopathy are often at risk of arrhythmia and/or sudden cardiac death.

Cardiomyopathies can generally be categorized into two groups: ischemic cardiomyopathy and nonischemic cardiomyopathy.

Ischemic cardiomyopathy is weakness in the muscle of the heart due to coronary artery disease. Individuals with ischemic cardiomyopathy typically have a history of myocardial infarction (heart attack).

Nonischemic

Nonischemic cardiomyopathy is weakness in the muscle of the heart that is not due to coronary artery disease. To make a diagnosis of nonischemic cardiomyopathy, significant coronary artery disease should be ruled out. The term nonischemic cardiomyopathy does not describe the etiology of weakened heart muscle. The nonischemic cardiomyopathies are a mixed-bag of disease states, each with their own causes.

Nonischemic cardiomyopathy has a number of causes including drug and alcohol toxicity, certain infections, and various genetic and idiopathic (i.e. unknown) causes.

Nonischemic subtypes

There are four main types of nonischemic cardiomyopathy:

Cardiomyopathy may also be related to Hepatitis C virus infection.

Treatment for non-ischemic cardiomyopathy

  • Standard treatment includes medical therapy and biventricular pacemaker. However, neither of these treatments improve the condition enough to prevent the need for an eventual heart transplant.
  • Alternative treatment using adult stem cells is commercially available outside the United States[1] for certain types of non-ischemic cardiomyopathy including idiopathic. Patients such as Jeannine Lewis[2], have traveled to Thailand to receive stem cell therapy for idopathic cardiomyopathy and have shown dramatic improvement[3]. Dr. Amit Patel of the University of Pittsburgh McGowen Institute for Regenerative Medicine[4] is one of the leaders in stem cell therapy for heart disease. Dr. Patel, pioneered the minimally invasive thorascopic injection technique used to implant the cells, which were harvested from a small amount of Mrs. Lewis' own blood, directly into her heart.